F.L. Putnam Investment Management’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $351K | Buy |
454
+44
| +11% | +$33.7K | 0.01% | 485 |
|
|
2025
Q4 | $316K | Sell |
410
-413
| -50% | -$280K | ﹤0.01% | 506 |
|
|
2025
Q3 | $463K | Sell |
823
-196
| -19% | -$111K | 0.01% | 426 |
|
|
2025
Q2 | $535K | Sell |
1,019
-482
| -32% | -$269K | 0.01% | 400 |
|
|
2025
Q1 | $952K | Sell |
1,501
-5,992
| -80% | -$4.12M | 0.02% | 323 |
|
|
2024
Q4 | $5.34M | Sell |
7,493
-12,619
| -63% | -$10.6M | 0.1% | 152 |
|
|
2024
Q3 | $21.1M | Sell |
20,112
-1,693
| -8% | -$1.88M | 0.38% | 56 |
|
|
2024
Q2 | $22.9M | Buy |
21,805
+2,303
| +12% | +$2.23M | 0.43% | 49 |
|
|
2024
Q1 | $18.8M | Buy |
19,502
+662
| +4% | +$629K | 0.4% | 57 |
|
|
2023
Q4 | $16.5M | Buy |
18,840
+87
| +0.5% | +$71.6K | 0.39% | 59 |
|
|
2023
Q3 | $15.4M | Buy |
18,753
+303
| +2% | +$238K | 0.43% | 52 |
|
|
2023
Q2 | $13.3M | Sell |
18,450
-99
| -0.5% | -$76.3K | 0.36% | 60 |
|
|
2023
Q1 | $15.2M | Buy |
18,549
+6
| +0% | +$4.53K | 0.5% | 46 |
|
|
2022
Q4 | $13.4M | Sell |
18,543
-28
| -0.2% | -$20.7K | 0.49% | 53 |
|
|
2022
Q3 | $12.8M | Buy |
18,571
+333
| +2% | +$210K | 0.5% | 45 |
|
|
2022
Q2 | $10.8M | Buy |
18,238
+153
| +0.8% | +$99.5K | 0.4% | 61 |
|
|
2022
Q1 | $12.6M | Sell |
18,085
-849
| -4% | -$537K | 0.4% | 56 |
|
|
2021
Q4 | $12M | Sell |
18,934
-89
| -0.5% | -$54.7K | 0.37% | 60 |
|
|
2021
Q3 | $11.5M | Buy |
19,023
+462
| +2% | +$287K | 0.39% | 62 |
|
|
2021
Q2 | $10.4M | Buy |
18,561
+475
| +3% | +$241K | 0.36% | 67 |
|
|
2021
Q1 | $8.56M | Sell |
18,086
-958
| -5% | -$466K | 0.38% | 62 |
|
|
2020
Q4 | $9.2M | Buy |
19,044
+1,042
| +6% | +$562K | 0.43% | 58 |
|
|
2020
Q3 | $10.1M | Sell |
18,002
-1,115
| -6% | -$676K | 0.55% | 49 |
|
|
2020
Q2 | $11.9M | Buy |
19,117
+1,021
| +6% | +$580K | 0.71% | 42 |
|
|
2020
Q1 | $8.84M | Buy |
18,096
+1,489
| +9% | +$614K | 0.67% | 49 |
|
|
2019
Q4 | $6.24M | Sell |
16,607
-705
| -4% | -$237K | 0.38% | 76 |
|
|
2019
Q3 | $4.8M | Sell |
17,312
-593
| -3% | -$175K | 0.34% | 84 |
|
|
2019
Q2 | $5.6M | Sell |
17,905
-1,072
| -6% | -$357K | 0.45% | 65 |
|
|
2019
Q1 | $7.79M | Sell |
18,977
-688
| -3% | -$283K | 0.65% | 52 |
|
|
2018
Q4 | $7.34M | Buy |
19,665
+321
| +2% | +$117K | 0.8% | 40 |
|
|
2018
Q3 | $7.82M | Buy |
19,344
+306
| +2% | +$116K | 0.72% | 47 |
|
|
2018
Q2 | $6.57M | Buy |
19,038
+539
| +3% | +$169K | 0.64% | 54 |
|
|
2018
Q1 | $6.37M | Sell |
18,499
-58
| -0.3% | -$20.2K | 0.58% | 54 |
|
|
2017
Q4 | $6.98M | Sell |
18,557
-1,618
| -8% | -$655K | 0.64% | 54 |
|
|
2017
Q3 | $9.02M | Buy |
+20,175
| New | +$9.6M | 0.86% | 38 |
|
|
2017
Q1 | $6.66M | Buy |
17,196
+2,487
| +17% | +$922K | 0.69% | 47 |
|
|
2016
Q4 | $5.4M | Sell |
14,709
-214
| -1% | -$81.4K | 0.62% | 55 |
|
|
2016
Q3 | $6M | Buy |
14,923
+61
| +0.4% | +$24.5K | 0.68% | 48 |
|
|
2016
Q2 | $5.19M | Buy |
+14,862
| New | +$5.72M | 0.62% | 52 |
|
Other funds holding REGN
VCM
N
F.L. Putnam Investment Management's REGN Position: Q1 2026 in Review
F.L. Putnam Investment Management increased its Regeneron Pharmaceuticals (REGN) stake by 11% in Q1 2026, buying an estimated $33.7K and bringing the position to 454 shares worth $351K. The position accounts for 0.01% of the portfolio, ranked #485.
F.L. Putnam Investment Management first reported a position in REGN in Q2 2016 and has held it in 39 quarters since. The position peaked at $22.9M in Q2 2024. 1,393 funds tracked by Wall St. Rank hold REGN as of Q1 2026.
- F.L. Putnam Investment Management held 454 shares of Regeneron Pharmaceuticals worth $351K as of Q1 2026.
- F.L. Putnam Investment Management bought 44 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $33.7K.
- Regeneron Pharmaceuticals made up 0.01% of F.L. Putnam Investment Management's portfolio in Q1 2026, its #485 holding.
- F.L. Putnam Investment Management first reported a position in Regeneron Pharmaceuticals in Q2 2016 and has held it in 39 quarters since.
- F.L. Putnam Investment Management's Regeneron Pharmaceuticals position peaked at $22.9M in Q2 2024.
- 1,393 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.
Based on F.L. Putnam Investment Management's 13F filing for Q1 2026, filed 5 May 2026.